$110.00Original price was: $110.00.$69.00Current price is: $69.00.
BPC-157 and TB-500 (Thymosin Beta-4) are peptides commonly studied for their potential in promoting tissue repair and healing. Both have distinct yet complementary mechanisms that, when combined, may offer synergistic benefits. BPC-157, a stable gastric pentadecapeptide, is derived from a protective protein found in the stomach lining. It has been shown in preclinical studies to accelerate healing of muscles, tendons, and ligaments by promoting angiogenesis (the formation of new blood vessels) and regulating the production of growth factors. Similarly, TB-500, a fragment of the naturally occurring Thymosin Beta-4 protein, plays a key role in cell migration, tissue regeneration, and reducing inflammation.
The potential synergy between these peptides arises from their overlapping yet distinct pathways in tissue repair. While BPC-157 excels at improving blood flow and reducing inflammation, TB-500 focuses on facilitating cellular migration to the injury site and supporting the repair process at the cellular level. Together, they may accelerate healing by addressing multiple aspects of tissue recovery, particularly in sports injuries or chronic conditions where regeneration is compromised. Early animal studies suggest this combination may lead to faster recovery times and improved structural integrity of repaired tissues.
It is crucial to note that while promising, much of the research on BPC-157 and TB-500 remains preclinical.
This combination of BPC-157 and TB-500 is typically administered via subcutaneous injection once daily, with doses adjusted based on the severity of the condition and desired therapeutic outcomes. A conservative starting point is 0.25 ml daily, delivering 250 mcg of each peptide. If well tolerated, this can be increased gradually over the first 2–3 weeks to 0.5 ml (500 mcg of each) per day.
For moderate to severe injuries or recovery enhancement, dosing may increase to 1 ml per day, providing 1 mg of each peptide. Many protocols include a 4–6 week daily dosing phase, followed by a taper or maintenance regimen at 0.25–0.5 ml every other day.
A typical protocol may look like:
Week 1–2: 0.25 ml daily (250 mcg each)
Week 3–4: Increase to 0.5 ml daily
Week 5+: Continue at 0.5–1 ml daily or as needed
Subcutaneous injections are best administered into the lower abdomen or thigh, with rotation of injection sites to avoid irritation. Localized injection near the site of injury is optional but may offer targeted benefit.
This combination features two of the most clinically studied regenerative peptides: BPC-157 and TB-500 (Thymosin Beta-4). Together, they work synergistically to enhance soft tissue repair, inflammation control, angiogenesis, and wound healing.
BPC-157 is a 15-amino-acid fragment derived from human gastric juice, known for its ability to support gut integrity, tendon healing, and cellular repair.
TB-500 is a synthetic analog of thymosin beta-4, a naturally occurring peptide involved in actin regulation, angiogenesis, and wound repair.
This pairing is ideal for supporting recovery from:
There is insufficient safety data for the use of either BPC-157 or TB-500 in pregnancy or during breastfeeding. While preclinical studies show no teratogenicity, use is not recommended during pregnancy or lactation.
These peptides have not been studied in pediatric populations, and use in individuals under 18 is not advised unless supervised by a pediatric specialist for clinically indicated regenerative therapy.
Neither BPC-157 nor Thymosin Beta-4 (TB-500) is currently FDA-approved
Both peptides are considered investigational compounds
This compounded formulation is not approved for any therapeutic indication, but is widely used in clinical research, sports medicine, and functional recovery protocols
